Renal cell carcinoma (RCC) represents a heterogeneous disease, encompassing an increasing number of tumor subtypes. Post-2016, the World Health Organization (WHO) classification recognized that the spectrum of papillary renal cell carcinoma is evolving and has long surpassed the dichotomic simplistic "type 1 versus type 2" classification. The differential diagnosis of pRCC includes several new provisional/emerging entities with papillary growth. Type 2 tumors have been cleared out of several confounding entities, now regarded as independent tumors with specific clinical and molecular backgrounds. In this work we describe the prevalence and characteristics of emerging papillary tumor entities in two renal tumor cohorts (one consisting of consecutive papillary tumors from a single institute, the other consisting of consultation cases from several centers). After a review of 154 consecutive pRCC cases, 58% remained type 1 pRCC, and 34% type 2 pRCC. Papillary renal neoplasm with reversed polarity (1.3%), biphasic hyalinizing psammomatous RCC (1.3%), and biphasic squamoid/alveolar RCC (4.5%) were rare. Among 281 consultation cases, 121 (43%) tumors had a dominant papillary growth (most frequently MiT family translocation RCCs, mucinous tubular and spindle cell carcinoma and clear cell papillary RCC). Our data confirm that the spectrum of RCCs with papillary growth represents a major diagnostical challenge, frequently requiring a second expert opinion. Papillary renal neoplasm with reversed polarity, biphasic hyalinizing psammomatous RCC, and biphasic squamoid/alveolar RCC are rarely sent out for a second opinion, but correct classification and knowledge of these variants will improve our understanding of the clinical behavior of renal tumors with papillary growth.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533532 | PMC |
http://dx.doi.org/10.3390/biomedicines9101418 | DOI Listing |
Cureus
December 2024
Gastroenterology and Hepatology, Aberdeen Royal Infirmary Hospital, Aberdeen, GBR.
Intraductal papillary neoplasm of the bile duct (IPNB) is a precursor lesion to biliary tract carcinoma. It is characterised by papillary growth within the bile ducts. The diagnosis and management of IPNB are challenging due to its varying presentations and overlapping features with other biliary diseases.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Faculty of Medicine of Tunis, Tunis El Manar University, Djebal Lakhdar Street, 1006 Tunis, Tunisia; Department of Pathology, Habib Thameur Hospital, 1082 Tunis, Tunisia. Electronic address:
Introduction And Importance: More needs to be understood concerning the natural progression and visual attributes of intracholecystic papillary neoplasm. Its longevity, especially the rate at which it transitions from benign to malignant growths, remains ambiguous. Consequently, it is imperative to elucidate the intrinsic progression of this precancerous lesion in the gallbladder.
View Article and Find Full Text PDFEndocr Relat Cancer
January 2025
A Nikitski, Department of Pathology, University of Pittsburgh, Pittsburgh, 15261, United States.
Approximately 10-20% of thyroid cancers are driven by gene fusions, which activate oncogenic signaling through aberrant overexpression, ligand-independent dimerization, or loss of inhibitory motifs. We identified 13 thyroid tumors with thyroglobulin (TG) gene fusions and aimed to assess their histopathology and the fusions' oncogenic and tumorigenic properties. Of 11 cases with surgical pathology, 82% were carcinomas and 18% noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP).
View Article and Find Full Text PDFGut
January 2025
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Background: Cyst size, its growth rate, and diameter of the main pancreatic duct (MPD) are all associated with pancreatic carcinoma prevalence in intraductal papillary mucinous neoplasms (IPMNs).
Objective: To examine the above factors in relation to future risk of incident pancreatic carcinoma in individuals with IPMNs harbouring no high-risk stigmata.
Design: In a prospective longitudinal cohort, we analysed 2549 patients with IPMNs.
Probl Endokrinol (Mosk)
March 2024
Background: KI-67 (MKI-67 in humans) is a protein able to bind to DNA which contributes to cell growth and cell proliferation. KI-67 is currently considered as a biomarker that is widely utilized as prognostic indicator for evaluating cell proliferation, diagnosing diseases, and conducting research. Several different kinds of cancer have high Ki-67 expression, which simplifying the choice of treatment for individuals with various cancer types.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!